For the first time ever, SCINTIX biology-guided radiotherapy uses the emissions from the cancer itself for live targeting of tumors at any stage.
SAME RADIOTRACERS, NEW ROLE
Powered by the rapidly expanding universe of radiopharmaceuticals, the RefleXion® X1 with SCINTIX technology uses emissions for live targeting of tumors at any stage. Initially using fludeoxyglucose F18 (FDG), only SCINTIX therapy will leverage disease-specific radiopharmaceuticals as they become available.
DUAL-TREATMENT MODALITY PLATFORM
ONE MACHINE. MULTIPLE TREATMENT MODALITIES.
The RefleXion X1 is designed to deliver SCINTIX therapy along with industry-leading CT-guided IMRT and SBRT. Equipped with fan-beam kVCT imaging, the X1 provides superior imaging for patient localization resulting in improved confidence for accurate dose delivery.
PICK A NUMBER, ONE THROUGH FOUR
SCINTIX therapy makes radiotherapy an option for patients with tumors in the bone or lung at any stage of cancer. Our breakthrough technology expands treatment to hundreds of thousands of patients across the U.S.
Finally, SCINTIX therapy solves the conundrum of tumor tracking by using emissions to produce live targeting information continuously updated with sub second latency during treatment. This approach reduces the need for motion management techniques such as gating or implanted fiducials and may result in lower toxicity to healthy tissue.
Be a Part of the Innovation
Participate in User Research and help drive the innovation yourself.